What is the Fiscal Year for Alzamend Neuro?
Date: November 13, 2026
Alzamend Neuro's current fiscal year starts on May 1, 2026, and ends on April 30, 2027. Their current quarter is Q3, which ends on January 31, 2027.
Current Fiscal Year Overview
Fiscal Year Start
May 1, 2026
Fiscal Year End
April 30, 2027
Current Quarter
Q3
Current Quarter End
January 31, 2027
Quarterly Breakdown
Q1
May 1, 2026 – Jul 31, 2026
Q2
Aug 1, 2026 – Oct 31, 2026
Q3
Nov 1, 2026 – Jan 31, 2027
Q4
Feb 1, 2027 – Apr 30, 2027
Company Information
Headquarters
Atlanta, Georgia
Industry
Biotechnology Research
Stock Symbol
ALZN
Website
https://alzamend.comDescription
Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, Bipolar disorder, Major Depressive Disorder (“MDD”) and Post-Traumatic Stress Disorder (“PTSD”). Our mission is to rapidly develop and market safe and effective treatments to bring aid to the 43+ Million Americans suffering from these debilitating diseases. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and ALZN002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Alzamend Neuro and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.